Aktuellt
SENASTE
Recorded sales improved to SEK 16.7m (17.9m in Q1 and SEK 0m in Q2 2023), and the cash balance was SEK 36m (39.9m in Q1 2024). The main difference is the support from recurring services related to VADA (with Day One as a partner) and the VRK1 program. Sprint BioScience continues to market and attracts interest from potential partners for TREX1 (DISA), NIMA and MASH programs, where the TREX-1 program attracted interest at the “Immuno-Oncology Summit Europe 2024” conference. Our Base Case ahead of Q2 was SEK 2.90 (Bull SEK 8.6 and Bear SEK 0.50).
LÄS MER
